Publicacions (219) Publicacions de PEDRO PÉREZ SEGURA

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Comprehensive splicing analysis of the alternatively spliced CHEK2 exons 8 and 10 reveals three enhancer/silencer-rich regions and 38 spliceogenic variants

    Journal of Pathology, Vol. 262, Núm. 4, pp. 395-409

  3. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

  4. Exploring gastric cancer genetics: A turning point in common variable immunodeficiency

    Journal of Allergy and Clinical Immunology: Global, Vol. 3, Núm. 2

  5. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

    Journal of Neuro-Oncology

  6. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  7. Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain

    Clinical and Translational Oncology

  8. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

  9. Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer

    Oral Oncology

  10. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology

  11. Response to Yilmaz et al.

    Anti-Cancer Drugs

  12. Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants

    Clinical chemistry, Vol. 70, Núm. 1, pp. 319-338

2023

  1. Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck

    Cancers, Vol. 15, Núm. 9

  2. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  3. Dermatologists might be the first to suspect hereditary leiomyomatosis and renal cell carcinoma syndrome

    Anais Brasileiros de Dermatologia, Vol. 98, Núm. 5, pp. 696-698

  4. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer

    Anti-Cancer Drugs, Vol. 34, Núm. 5, pp. 695-698

  5. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2

    Viruses, Vol. 15, Núm. 7

  6. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities

    Cancers, Vol. 15, Núm. 12

  7. Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers

    Current Oncology, Vol. 30, Núm. 3, pp. 2569-2581

  8. Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 14